Prima BioMed secures European patent grant for lead product IMP321 in cancer
Prima BioMed announces the grant of patent number 2604275 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the European Patent Office. This European patent was filed as a divisional application and follows the grant of the European parent patent, which was issued in August 2013. The claims of this new patent are geared toward the use of Prima's lead candidate IMP321 in combination with a chemotherapeutic agent for the treatment of cancer. According to the claims, IMP321 elicits a monocyte-mediated immune response and is administered before, with, or subsequent to administration of the chemotherapeutic agent. Importantly, these granted claims support the application of IMP321 in Prima's AIPAC clinical trial in metastatic breast cancer in Europe. The patent expiry date is 3 October 2028.